Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
4
Expiration
Dec 4, 2026
DTE
21d
Moneyness
ITM
Intrinsic
$2.01
IBRX 4 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $4.14 | +8.66% | 20 | 63 |
| Nov 20, 2026 | 7d | $4.45 | +6.71% | 1 | 19 |
| Nov 27, 2026 | 14d | $4.50 | +10.29% | 2 | 15 |
| Dec 4, 2026 | 21d | $4.50 | +3.45% | 4 | 4 |
| Dec 11, 2026 | 28d | $4.50 | +0.00% | 2 | 1 |
| Dec 18, 2026 | 35d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $5.00 | +11.36% | 1 | 5,566 |
| Mar 19, 2027 | 126d | $5.10 | -21.42% | 1 | 238 |
| Apr 16, 2027 | 154d | — | — | 0 | 0 |
| May 21, 2027 | 189d | $4.24 | +0.00% | 1 | 1 |
| Aug 20, 2027 | 280d | — | — | 0 | 30 |
| Nov 19, 2027 | 371d | — | — | 0 | 0 |
| Jan 21, 2028 | 434d | $6.75 | -1.75% | 15 | 2,163 |
| Mar 17, 2028 | 490d | $5.25 | -9.48% | 2 | 1 |
| Jan 19, 2029 | 798d | $6.03 | -16.25% | 9 | 57 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.